Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Typhoid conjugate vaccine booster dose study
ISRCTN18281619Phase 3Terminated
- Sponsor
- University of Oxford
- Start
- Dec 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in typhoid fever comparing Homologous booster with Tybar-TCV with Heterologous booster with TYPHIBEV (2 arms). Primary endpoints: Primary immunogenicity endpoint and Previous primary immunogenicity endpoint. Started Dec 2025; status: terminated.
02
Drugs
Typbar-TCVtyphoid conjugate vaccine
03
Conditions
typhoid fever
Beyond the preview
Go deeper on ISRCTN18281619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN18281619.